You can buy or sell Auris Medical and other stocks, options, and ETFs commission-free!
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in 2003 and is headquartered in Hamilton, Bermuda. The listed name for EARS is Auris Medical Holding Ltd. Common Shares 0.01 SF (Bermuda).
52 Week High
52 Week Low
— per share
Expected Mar 16, Pre-Market